Effect of γ-hydroxybutyrate on central dopamine release in vivo

Biochemical Pharmacology

Volumn 53, Issue 1, 1997, Pages 103-110

  Howard, Sherrel G ^a   Feigenbaum, Jeffery J ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Executive House ^*  (United States)

Author keywords

anesthetized rat; conscious rat; hydroxybutyrate; in vivo; microdialysis; striatal dopamine release

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; 4 HYDROXYBUTYRIC ACID; DOPAMINE; HOMOVANILLIC ACID; URETHAN;

ANESTHESIA; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE RELEASE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MICRODIALYSIS; NONHUMAN; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION; WAKEFULNESS;

ANIMALS; CORPUS STRIATUM; DOPAMINE; MALE; RATS; RATS, SPRAGUE-DAWLEY; SODIUM OXYBATE; URETHANE;

EID: 0031060619     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(96)00664-8     Document Type: Article

References (67)

1. Bessman SP and Fishbein WN, Gamma-hydroxybutyrate, a normal brain metabolite. Nature Lond 200: 1207-1208, 1963.
2. Roth RH and Suhr Y, Mechanism of γ-hydroxybutyrate-induced increase in brain dopamine and its relationship to "sleep." Biochem Pharmacol 19: 3001-3012, 1970.
3. Chéramy A, Nieoullon A and Glowinski J, Stimulating effects of γ-hydroxybutyrate on dopamine release from the caudate nucleus and the substantia nigra of the cat. J Pharmacol Exp Ther 203: 283-293, 1977.
4. Maitre M, Hechler V, Vayer P, Gobaille S, Cash CD, Schmitt M and Bourguignon J-J, A specific γ-hydroxybutyrate receptor ligand possesses both antagonistic and anticonvulsant properties. J Pharmacol Exp Ther 255: 657-663, 1990.
5. Hechler V, Gobaille S, Bourguignon J-J and Maitre M, Extracellular events induced by γ-hydroxybutyrate in striatum: A microdialysis study. J Neurochem 56: 938-944, 1991.
6. Nissbrandt H, Elverfors A and Engberg G, Pharmacologically induced cessation of burst activity in nigral dopamine neurons: Significance for the terminal dopamine efflux. Synapse 17: 217-224, 1994.
7. Mamelak M, Gammahydroxybutyrate: An endogenous regulator of energy metabolism. Neurosci Biobehav Rev 13: 187-198, 1989.
8. Gobaille S, Schmidt C, Cupo A, Herbrecht F and Maitre M, Characterization of methionine-enkephalin release in the rat striatum by in vivo dialysis: Effects of gamma-hydroxybutyrate on cellular and extracellular methionine-enkephalin levels. Neuroscience 60: 637-648, 1994.
9. Paxinos G and Watson C, The Rat Brain in Stereotaxic Coordinates. Academic Press, New York, 1986.
10. Lane RF and Blaha CD, Acute thioridazine stimulates mesolimbic but not nigrostriatal dopamine release: Demonstration by in vivo electrochemistry. Brain Res 408: 317-320, 1987.
11. Zhang WQ, Tilson HA, Nanry KP, Hudson PM, Hong JS and Stachowiak MK, Increased dopamine release from striata of rats after unilateral nigrostriatal bundle damage. Brain Res 461: 335-342, 1988.
12. Van Valkenburg CFM, Noach EL and Wijling A, Involvement of the nerve impulse flow in the release of extragranular dopamine. Eur J Pharmacol 57: 191-197, 1979.
13. Bettini E, Ceci A, Spinelli R and Samanin R, Neurolepticlike effects of the l-isomer of fenfluramine on striatal dopamine release in freely moving rats. Biochem Pharmacol 36: 2387-2391, 1987.
14. Brown EE, Damsma G, Cumming P and Fibiger HC, Interstitial 3-methoxy-tyramine reflects striatal dopamine release: An in vivo microdialysis study. J Neurochem 57: 701-707, 1991.
15. Bustos G and Roth RH, Effect of γ-hydroxybutyrate on the release of monoamines from the rat striatum. Br J Pharmacol 44: 817-820, 1972.
16. Bustos G and Roth RH, Release of monoamines from the striatum and hypothalamus: Effect of γ-hydroxybutyrate. Brit J Pharmacol 46: 101-115, 1972.
17. Di Giulio AM, Groppetti A, Cattabeni F, Galli CL, Maggi A, Algeri S and Ponzio F, The significance of dopamine metabolites in the evaluation of drugs acting on dopaminergic neurons. Eur J Pharmacol 52: 201-207, 1978.
18. Abraini JH, Raharison L and Rostain JC, Long-term depression in striatal dopamine release monitored by in vivo voltammetry in free moving rats. Brain Res 548: 256-259, 1991.
19. Alter CA, O'Neil S and Marhsall JF, Sensorimotor impairment and elevated levels of dopamine metabolites in the neostriatum occur rapidly after intranigral injection of 6-hydroxy-dopamine or gamma-hydroxybutyrate in awake rats. Neuropharmacology 23: 309-318, 1984.
20. Imperato A and Di Chiara G, Trans-striatal dialysis coupled to reverse phase high performance liquid chromatography with electrochemical detection: A new method for the study of the in vivo release of endogenous dopamine and metabolites. J Neurosci 4: 966-977, 1984.
21. Imperato A and Di Chiara G, Dopamine release and metabolism in awake rats after systemic neuroleptics as studied by trans-striatal dialysis. J Neurosci 5: 297-306, 1985.
22. Imperato A and Di Chiara G, Preferential stimulation of dopamine release in the nucleus accumbens of freely moving rats by ethanol. J Pharmacol Exp Ther 239: 219-228, 1986.
23. Imperato A, Mulas A and Di Chiara G, The D-1 antagonist SCH 23390 stimulates while the D-1 agonist SKF 38393 fails to affect dopamine release in the dorsal caudate of freely moving rats. Eur J Pharmacol 142: 177-181, 1987.
24. Lane RF, Electrochemistry in vivo: Monitoring dopamine release in the brain of the conscious freely moving rat. Brain Res Bull 19: 19-27, 1987.
25. Roth RH, Striatal dopamine and gamma-hydroxybutyrate. Pharmacology and Therapeutics 2: 71-88, 1976.
26. Roth RH, Walters JR and Aghajanian GK, Effect of impulse flow on the release and synthesis of dopamine in rat striatum. In: Frontiers in Catecholamine Research (Eds. Usdin E and Snyder S), pp. 567-574. Pergamon Press, New York, 1973.
27. Santiago M and Westerink BHC, Characterization and phar-macological responsiveness of dopamine release recorded by microdialysis in the substantia nigra of conscious rats. J Neurochem 57: 738-747, 1991.
28. Westerink BHC, Effects of drugs on the formation of 3-methoxytyramine, a dopamine metabolite, in the substantia nigra, striatum, nucleus accumbens and tuberculum olfactorium of the rat. J Pharm Pharmacol 31: 94-99, 1979.
29. Westerink HC and Spaan SJ, On the significance of endogenous 3-methoxy-tyramine for the effects of centrally acting drugs on dopamine release in the rat brain. J Neurochem 38: 680-686, 1982.
30. 3H-dopamine in the striatum: An adaptation of the push-pull cannula method to awake and restrained rats. Brain Res Bull 16: 149-154, 1986.
31. Saratikov AS, Zamoshchina TA, Alekseeva LP and Agarkova VP, Influence of hydroxybutyrate on the electroencephalographic effects of fenamin. Biull Eksp Biol Med 94: 46-49, 1982.
32. Cott J and Engel J, Suppression by GABAergic drugs of the locomotor stimulation induced by morphine, amphetamine, and apomorphine: Evidence for both pre-and post-synaptic inhibition of catecholamine systems. J Neural Transm 40: 253-268, 1977.
33. Feigenbaum J, Yanai J, Klawans H and Moon B, Differential catecholamine uptake inhibition as a possible mode of action of d-amphetamine induced locomotor activity. Res Commun Chem Pathol Pharmacol 39: 349-352, 1983.
34. Tolpyschev BA, Influence of GABA-ergic substances on the effects of caudate nucleus stimulation and fenamin stereotyping in cats. Farmakol Toksikol 43: 140-144, 1980.
35. Ellinwood EH, Gonzalez AE and Dougherty GG, γ-Butyrolactone effects on behavior induced by dopamine agonists. Biol Psychiatry 18: 1023-1032, 1983.
36. Menon K, Bieger D and Homykiewicz O, Pharmacological evidence for a selective antidopaminergic action of gamma-hydroxybutyric acid. J Neural Transm 39: 177-186, 1976.
37. Dudek BC, and Fanelli RJ, Effects of gamma-butyrolactone, amphetamine, and haloperidol in mice differing in sensitivity to alcohol. Psychopharmacology 68: 89-97, 1980.
38. Herdon H, Srupish J and Nahorski SR, Differences between the release of radiolabelled and endogenous dopamine from superfused rat brain slices: Effects of depolarizing stimuli, amphetamine and synthesis inhibition. Brain Res 384: 309-320, 1985.
39. Jhamandas K and Marien MR, Glutamate-evoked release of endogenous brain dopamine: Inhibition of an excitatory amino acid antagonist and an enkephalin analogue. Br J Pharmacol 90: 641-650, 1987.
40. Clow DW and Jhamandas K, Effects of a κ-receptor agonist, U-50, 488H, on the release of endogenous brain dopamine. Can J Physiol Pharmacol 66: 128-133, 1988.
41. Starr MS, The modulation of dopamine release by GABA in the central nervous system. In: Presynaptic Regulation of Neurotransmitter Release: A Handbook (Eds. Feigenbaum JJ and Hanani M), Vol. 2, pp. 613-649. Freund, London, 1991.
42. Costentin J, Marçais H, Protais P, Baudry M, De La Baume S, Martres M-P and Schwartz J-C, Rapid development of hypersensitivity of striatal dopamine receptors induced by alpha-methylparatyrosine and its prevention by protein synthesis inhibitors. Life Sci 21: 307-314, 1977.
43. Henderson RS and Holmes C, Reversal of the anaesthetic action of sodium gamma-hydroxybutyrate. Anaesth Intensive Care 4: 351-360, 1976.
44. 3H]tyrosine in the cat cau-date nucleus: Effects of various physical and pharmacological treatments. J Neurochem 28: 819-828, 1977.
45. Collin A-K, Stahle L and Ungerstedt U, Effects of halothane anaesthesia on extracellular levels of DA, DOPAC, HVA and 5-HIAA in rat striatum. Acta Physiol Scand 132: 30A, 1988.
46. Lillrank SM, O'Connor WT, Oja SS and Ungerstedt U, Systemic phencyclidine administration is associated with increased dopamine, GABA, and 5-HIAA levels in the dorsolateral striatum of conscious rats: An in vivo microdialysis study. J Neural Transm 95: 145-155, 1994.
47. Stahle L, Collin A-K and Ungerstedt U, Effects of halothane anaesthesia on extracellular levels of dopamine, dihydroxyphenylacetic acid, homovanillic acid and 5-hydroxyindoleacetic acid in rat striatum: A microdialysis study. Naunyn Schmiedebergs Arch Pharmacol 342: 136-140, 1990.
48. Osborne PG, O'Connor WT, Drew KL and Ungerstedt U, An in vivo characterization of extracellular dopamine and GABA in the dorsolateral striatum of awake, moving and halothane anaesthetized rats. J Neurosci Methods 37: 93-102, 1991.
49. 3H]dopamine release in anesthetized, awake restrained and freely moving rats. Brain Res Bull 16: 161-166, 1986.
50. Miano K, Tanifuji Y and Eger EL, The effect of halothane dose on striatal dopamine: an in vivo microdialysis study. Brain Res 605: 342-344, 1993.
51. Westerink BHC, Hofsteede HM, Damsma G and de Vries JB, The significance of extracellular calcium for the release of dopamine, acetylcholine, and amino acids in conscious rats, evaluated by brain microdialysis. Naunyn Schmied Arch Pharmacol 337: 373-378, 1988.
52. Moghaddam B and Bunney BS, Ionic composition of microdialysis perfusing solution alters the pharmacological responsiveness and basal outflow of striatal dopamine. J Neurochem 53: 652-654, 1989.
53. DeBoer P, Damsma G, Fibiger HC, Timmerman W, de Vries JB and Westerink BHC, Dopaminergic-cholinergic interactions in the striatum: The critical significance of calcium concentrations in brain microdialysis. Naunyn Schmied Arch Pharmacol 342: 528-534, 1990.
54. 2 agonists on the release of dopamine in the striatum of the rat. Neurosci Lett 131: 93-96, 1991.
55. Zhang W, Tilson H, Stachowiak MK and Hong JS, Repeated haloperidol administration changes basal release of striatal dopamine and subsequent response to haloperidol challenge. Brain Res 484: 389-392, 1989.
56. Hamilton ME, Mele A and Pert A, Striatal extracellular dopamine in conscious vs. anaesthetized rats: Effects of chloral hydrate anaesthetic on responses to drugs of different classes. Brain Res 597: 1-7, 1992.
57. Nielsen JA and Moore KE, Effects of chloral hydrate, γ-butyrolactone, and equithesin on the efflux of dopamine and 5-hydroxytryptamine metabolites into cerebroventricular perfusates of rats. J Neurochem 39: 235-238, 1982.
58. Clemens JA and Phebus LA, Changes in brain chemistry produced by dopaminergic agents: In vivo electrochemical monitoring reveals opposite changes in anaesthetized vs unanesthetized rats. Brian Res 267: 183-186, 1983.
59. Bunney BS, Walter JR, Roth RH and Aghajanian GK, Dopaminergic neurons: Effect of antipsychotic drugs and amphetamine on single cell activity. J Pharmacol Exp Ther 185: 560-571, 1974.
60. Bergstrom DA, Bromley SD, and Walters JR, Dopamine agonists increase pallidal unit activity: Attenuation by agonist pretreatment and anaesthesia. Eur J Pharmacol 100: 3-12, 1984.
61. Carlson JH, Bergstrom DA, Weick BG and Walters JR, Neurophysiological investigation of effects of the D-1 agonist SKF 38393 on tonic activity of substantia nigra dopamine neurons. Synapse 1: 411-416, 1987.
62. Cessa GL, Agonist and antagonist actions of lisuride on dopamine neurons: Electrophysiological evidence. J Neural Trans Suppl 27: 201-210, 1988.
63. Kelland MD, Freeman AS and Chiodo LA, Chloral hydrate anaesthesia alters the responsiveness of identified midbrain neurons to dopamine agonist administration. Synapse 3: 30-37, 1989.
64. 1 agonist SKF 38393 increases dopamine release in the developing striatum. Eur J Pharmacol 184: 257-264, 1990.
65. Propesko P, Rajtova V and Harak J, A Color Atlas of Anatomy of Small Laboratory Animals, Vol. 9, pp. 69-70. Wolfe Publishing, London, 1990.
66. B receptors. Naunyn-Schmiedebergs Arch Pharmacol 348: 491-497, 1993.
67. Feigenbaum JJ and Howard SG, Gamma hydroxybutyrate is not a GABA agonist. Prog Neurobiol, in press.